NEWS - Mar 9, 2026 Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference Read more
NEWS - Mar 9, 2026 Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing Read more
NEWS - Mar 9, 2026 Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer Read more
NEWS - Jan 12, 2026 Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications Read more
NEWS - Dec 3, 2025 Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology Read more
NEWS - Nov 13, 2025 Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates Read more
NEWS - Nov 7, 2025 Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 Read more
NEWS - Nov 4, 2025 Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Read more
NEWS - Nov 4, 2025 Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer Read more
NEWS - Oct 7, 2025 Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 Read more
